Gregory D. Davis - Oct 18, 2024 Form 3 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: Head of Research & Technology
Signature: /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: SGMO
Transactions as of: Oct 18, 2024
Transactions value $: $0
Form type: 3
Date filed: 10/28/2024, 04:11 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGMO	Common Stock						203K	Oct 18, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SGMO	Stock Option (Right to Buy)							Oct 18, 2024	Common Stock	60K	$9.16	Direct	F2
holding	SGMO	Stock Option (Right to Buy)							Oct 18, 2024	Common Stock	25K	$11.19	Direct	F3
holding	SGMO	Stock Option (Right to Buy)							Oct 18, 2024	Common Stock	27.2K	$5.90	Direct	F4
holding	SGMO	Stock Option (Right to Buy)							Oct 18, 2024	Common Stock	64.7K	$2.66	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1. Includes (a) 2,836 shares subject to the Reporting Person's February 25, 2022 restricted stock unit ("RSU") grant that will vest in successive equal quarterly installments through February 25, 2025, (b) 12,129 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
F2	Fully vested and exercisable.
F3	One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2021 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F4	One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2022 grant date, and the remainder of the shares subject to the option vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F5	One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 24, 2023 grant date, and the remainder of the shares subject to the option will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.